Showing results (1641-1650 of 1,873) with videos related to

Sort By:
Pageof 188
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2020
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted RadioimmunotherapyBrian H Santich, Sarah M Cheal, Mahiuddin Ahmed, et al.
Cell Reports|December 2, 2020
Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung CancerCorrin A Wohlhieter, Allison L Richards, Fathema Uddin, et al.
Nature|September 17, 2025
Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancerAbbie S Ireland, Daniel A Xie, Sarah B Hawgood, et al.
Cell Reports|May 18, 2022
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLCHirokazu Taniguchi, Rebecca Caeser, Shweta S Chavan, et al.
Science (New York, N.Y.)|September 4, 2009
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastomaRobert L Yauch, Gerrit J P Dijkgraaf, Bruno Alicke, et al.
Clinical Lung Cancer|October 1, 2016
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor MutationsNatasha B Leighl, Naiyer A Rizvi, Lopes Gilberto de Lima, et al.
Cell|September 7, 2024
TGF-β and RAS jointly unmask primed enhancers to drive metastasisJun Ho Lee, Francisco J Sánchez-Rivera, Lan He, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostateSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Annals of the Rheumatic Diseases|April 5, 2025
Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment armMerete Lund Hetland, Marte S Heiberg, Tuulikki Sokka-Isler, et al.
BMC Rheumatology|April 21, 2025
Transitional and CD21- PD-1+ B cells are associated with remission in early rheumatoid arthritisSarah McGrath, Boel Sundbeck, Katrin Thorarinsdottir, et al.
Pageof 188